S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
66,000% upside on tiny biotech? (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Bank Collapse Causes Gold Prices to Soar (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
66,000% upside on tiny biotech? (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Bank Collapse Causes Gold Prices to Soar (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
66,000% upside on tiny biotech? (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Bank Collapse Causes Gold Prices to Soar (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
66,000% upside on tiny biotech? (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Bank Collapse Causes Gold Prices to Soar (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
NASDAQ:XBIT

XBiotech (XBIT) Stock Forecast, Price & News

$5.47
+0.08 (+1.48%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$5.10
$5.74
50-Day Range
$3.06
$5.73
52-Week Range
$3.00
$6.49
Volume
125,000 shs
Average Volume
60,248 shs
Market Capitalization
$166.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

XBIT stock logo

About XBiotech (NASDAQ:XBIT) Stock

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

XBIT Stock News Headlines

XBiotech (NASDAQ:XBIT) Coverage Initiated at StockNews.com
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
XBiotech (NASDAQ:XBIT) Now Covered by StockNews.com
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
StockNews.com Upgrades XBiotech (NASDAQ:XBIT) to "Hold"
See More Headlines
Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

XBIT Company Calendar

Today
5/29/2023
Next Earnings (Estimated)
5/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XBIT
Employees
97
Year Founded
N/A

Profitability

Net Income
$-32,900,000.00
Net Margins
-820.45%
Pretax Margin
-882.82%

Debt

Sales & Book Value

Annual Sales
$4.01 million
Book Value
$7.90 per share

Miscellaneous

Free Float
21,977,000
Market Cap
$166.51 million
Optionable
Optionable
Beta
1.22

Key Executives

  • John SimardJohn Simard
    Chairman, President & Chief Executive Officer
  • Ashley Otero
    Vice President-Clinical Operations
  • Angela Hu
    Chief Financial & Accounting Officer
  • Sushma Shivaswamy
    Chief Scientific Officer
  • Mark Ziats
    Medical Director













XBIT Stock - Frequently Asked Questions

How have XBIT shares performed in 2023?

XBiotech's stock was trading at $3.51 at the start of the year. Since then, XBIT stock has increased by 55.8% and is now trading at $5.47.
View the best growth stocks for 2023 here
.

Are investors shorting XBiotech?

XBiotech saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 83,800 shares, an increase of 23.1% from the April 30th total of 68,100 shares. Based on an average trading volume of 67,700 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.5% of the company's stock are sold short.
View XBiotech's Short Interest
.

When is XBiotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 30th 2023.
View our XBIT earnings forecast
.

What is John Simard's approval rating as XBiotech's CEO?

20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ).

When did XBiotech IPO?

(XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Who are XBiotech's major shareholders?

XBiotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (0.25%), Connor Clark & Lunn Investment Management Ltd. (0.19%), Two Sigma Investments LP (0.18%), Renaissance Technologies LLC (0.17%), Two Sigma Advisers LP (0.16%) and Susquehanna International Group LLP (0.13%). Insiders that own company stock include John Simard, Queena Han, Street Financial SA Bay, Sushma Shivaswamy and W Thorpe Mckenzie.
View institutional ownership trends
.

How do I buy shares of XBiotech?

Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $5.47.

How much money does XBiotech make?

XBiotech (NASDAQ:XBIT) has a market capitalization of $166.51 million and generates $4.01 million in revenue each year. The biopharmaceutical company earns $-32,900,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The official website for the company is www.xbiotech.com. The biopharmaceutical company can be reached via phone at (512) 386-2900, via email at swhitehurst@xbiotech.com, or via fax at 512-386-5505.

This page (NASDAQ:XBIT) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -